Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02585024
Registration number
NCT02585024
Ethics application status
Date submitted
21/10/2015
Date registered
23/10/2015
Date last updated
22/03/2019
Titles & IDs
Public title
Cytisine Pharmacokinetics and Dose Response (C-DRAKS 3 and C-DRAKS 4)
Query!
Scientific title
Cytisine as a Smoking Cessation Agent: Improving Adherence Through a Better Understanding of Pharmacokinetics and Dose Response
Query!
Secondary ID [1]
0
0
AMRF reference 1 1 15 011
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Smoking Cessation
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cytisine
Experimental: 1.5 mg cytisine - 1.5 mg cytisine given as a single dose
Experimental: 3 mg cytisine - 3 mg cytisine given as a single dose
Experimental: 4.5 mg cytisine - 4.5 mg cytisine given as a single dose
Experimental: 1.5 mg cytisine six times a day - 1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
Experimental: 3 mg cytisine three times a day - 3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
Experimental: 4.5 mg cytisine two times a day - 4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
Treatment: Drugs: Cytisine
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Exposure (AUC)
Query!
Assessment method [1]
0
0
Plasma cytisine concentrations will be measured in all groups for 24 hours. For Arms 4-6, we will continue to take blood samples to measure cytisine concentrations throughout the dosing period (Days 1-5). Days 3-5: one blood sample will be taken before the first dose for the day. On Day 5 an extra blood sample will be taken at 7.5 hours post the first dose for that day.
Query!
Timepoint [1]
0
0
Arms 1-3: 24 hours; Arms 4-6: 24 hours, and up to Day 5
Query!
Secondary outcome [1]
0
0
Nicotine and cotinine concentrations
Query!
Assessment method [1]
0
0
Plasma nicotine and cotinine concentrations will be measured along with cytisine concentrations (from the same plasma samples)
Query!
Timepoint [1]
0
0
Arms 1-3: 24 hours; Arms 4-6: 24 hours, and up to Day 5
Query!
Secondary outcome [2]
0
0
Craving for cigarettes
Query!
Assessment method [2]
0
0
The brief Questionnaire on Smoking Urges will be administered
Query!
Timepoint [2]
0
0
Arms 1-3: 0, 1, 2, 4, 6, 8, 10 and 24 hours. Arms 4-6: 0, 2, 4 ,6, 8, 10, 24 hours; once on Days 3- 5
Query!
Secondary outcome [3]
0
0
Blood pressure
Query!
Assessment method [3]
0
0
Systolic and diastolic blood pressure (mm Hg) will be measured with a blood pressure monitor
Query!
Timepoint [3]
0
0
Arms: 1-3: 0, 1, 2, 4, 6, 8, 10, 24 hours. Arms 4-6: 0, 2, 4, 6, 8, 10, 24 hours; once on Days 3- 5
Query!
Secondary outcome [4]
0
0
Heart rate
Query!
Assessment method [4]
0
0
Heart rate (beats per minute) will be simultaneously measured with blood pressure using a blood pressure monitor
Query!
Timepoint [4]
0
0
Arms: 1-3: 0, 1, 2, 4, 6, 8, 10, 24 hours. Arms 4-6: 0, 2, 4, 6, 8, 10, 24 hours; once on Days 3- 5
Query!
Secondary outcome [5]
0
0
Respiratory rate
Query!
Assessment method [5]
0
0
Respiratory rate (breaths per minute) will be measured along with blood pressure and heart rate
Query!
Timepoint [5]
0
0
Arms: 1-3: 0, 1, 2, 4, 6, 8, 10, 24 hours. Arms 4-6: 0, 2, 4, 6, 8, 10, 24 hours; once on Days 3- 5
Query!
Eligibility
Key inclusion criteria
- be at least 18 years of age,
- be able to provide written consent,
- have no significant medical or psychiatric disorder (see below under exclusion
criteria)
- smoke at least 10 cigarettes a day
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- they are pregnant or breastfeeding,
- they are current users of NRT products,
- they are current users of non-NRT smoking cessation therapies (e.g. bupropion
[Zyban®], clonidine, nortriptyline, or varenicline [Champix®]),
- they are enrolled in another smoking cessation programme (concurrent referral to a
face-to-face provider from Quitline is acceptable) or other cessation study
- they have had a heart attack, stroke, or severe angina within the past three months,
- they have uncontrolled high blood pressure (> 150 mmHg systolic, > 100 mmHg
diastolic),
- they have phaeochromocytoma,
- they have been diagnosed with epilepsy
- they suffer from significant mental health problems
- they have severe renal impairment
- they are taking medications which are significantly affected by cessation of smoking
(e.g. warfarin, olanzapine, clozapine, therophylline, etc.)
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
35
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
University of Auckland, New Zealand
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A number of pharmacotherapies are available for smoking cessation in New Zealand including
nicotine replacement therapy, bupropion, an antidepressant medication and varenicline. Of
these, varenicline is the most effective, but also the most expensive. Varenicline acts like
nicotine and stimulates nicotine receptors in the brain, but to a lesser extent, and
simultaneously block nicotine binding to its receptors and thus reduces the rewarding effects
of cigarette smoking. Cytisine (Tabex® and Desmoxan®) is a plant alkaloid and also acts in a
similar way to varenicline but is significantly cheaper. It has been used for more than 50
years in some parts of eastern and central Europe as an aid to quit smoking, but is not
approved for use in many countries such as New Zealand, Australia, the UK or the US.
Randomised, placebo-controlled trials have shown that cytisine is more effective than placebo
and nicotine replacement therapy (NRT)for smoking cessation. However there is a paucity of
pre-clinical data on cytisine. In particular, there are limited data on the pharmacokinetic
and the dose response characteristics of cytisine. Furthermore, the current dosing regimen
recommended by the manufacturer is complex and has no clear basis in empirical research.
Complexity of dosing has been shown to be a key factor in determining adherence. Therefore, a
simpler regimen would likely maximise the effectiveness of treatment through improved
adherence to the treatment regimen. The investigators therefore propose to undertake two
studies to investigate the influence of dose, dosing frequency and dosing duration on the
pharmacokinetics and tolerability of cytisine and cigarette craving in smokers.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02585024
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Soo Hee Jeong, Phd
Query!
Address
0
0
University of Auckland, New Zealand
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02585024
Download to PDF